Loading…
Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog
A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administrati...
Saved in:
| Published in: | International journal of pharmaceutics 2004-05, Vol.276 (1), p.75-81 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23 |
| container_end_page | 81 |
| container_issue | 1 |
| container_start_page | 75 |
| container_title | International journal of pharmaceutics |
| container_volume | 276 |
| creator | Jansen, Mendel Darby, Ian Abribat, Thierry Dubreuil, Pascal Ferdinandi, Eckhardt S Hardy, John G |
| description | A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administration is being considered as an alternative to subcutaneous injection. A study was undertaken in dogs to investigate the absorption of TH9507 following pulmonary delivery. Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38
μg/kg, respectively. In a separate study, male and female dogs received 100
μg/kg intravenously. Blood samples were collected at selected sampling times after dosing and plasma levels of TH9507 were measured by radioimmunoassay. The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%. No significant difference was observed for the terminal half-life of TH9507 after intratracheal (39
min) and subcutaneous (26
min) administrations. The mean residence time (MRT) was greater following intratracheal administration (74
min versus 52
min;
P |
| doi_str_mv | 10.1016/j.ijpharm.2004.02.012 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71872382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517304001164</els_id><sourcerecordid>71872382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23</originalsourceid><addsrcrecordid>eNqFkUtv1DAQgC0EotvCT6DyBU6b4EdsZ08IVbRFqgSH5Ww59njXqyRe7KQV_x6vNlJ762nm8M3rG4Q-UVJTQuXXQx0Ox71JQ80IaWrCakLZG7SireIVb5R8i1aEq7YSVPELdJnzgRAiGeXv0QUVlHJJ5Qptf8_9EEeT_mEHfXiEkkSPt_cbQdQaG7xL8Wna431MBQOcoAeTw7jD3tgpJmxG08fdDGscRjztAbu4-4DeedNn-LjEK_Tn9sf25r56-HX38-b7Q2X5hk5V13UgjGKyZZJyJRqniFRCGOcdpw110jMjRNOA6KyjUgjnfLmPbWTLvWf8Cn059z2m-HeGPOkhZAt9b0aIc9bqBPP2BIozaFPMOYHXxxSGcrSmRJ906oNedOqTTk2YLjpL3fUyYO4GcM9Vi78CfF4Ak63pfTKjDfkFp1hTflG4b2cOio7HAElnG2C04EICO2kXwyur_AeNYJRs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71872382</pqid></control><display><type>article</type><title>Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog</title><source>Elsevier</source><creator>Jansen, Mendel ; Darby, Ian ; Abribat, Thierry ; Dubreuil, Pascal ; Ferdinandi, Eckhardt S ; Hardy, John G</creator><creatorcontrib>Jansen, Mendel ; Darby, Ian ; Abribat, Thierry ; Dubreuil, Pascal ; Ferdinandi, Eckhardt S ; Hardy, John G</creatorcontrib><description>A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administration is being considered as an alternative to subcutaneous injection. A study was undertaken in dogs to investigate the absorption of TH9507 following pulmonary delivery. Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38
μg/kg, respectively. In a separate study, male and female dogs received 100
μg/kg intravenously. Blood samples were collected at selected sampling times after dosing and plasma levels of TH9507 were measured by radioimmunoassay. The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%. No significant difference was observed for the terminal half-life of TH9507 after intratracheal (39
min) and subcutaneous (26
min) administrations. The mean residence time (MRT) was greater following intratracheal administration (74
min versus 52
min;
P<0.01). These data indicate that the delivery of the TH9507 by the inhalation route may provide a suitable alternative to subcutaneous injection.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2004.02.012</identifier><identifier>PMID: 15113616</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Absorption ; Animals ; Area Under Curve ; Bioavailability ; Biological and medical sciences ; Biological Availability ; Dogs ; Female ; General pharmacology ; Growth Hormone-Releasing Hormone - analogs & derivatives ; Half-Life ; hGRF ; Injections, Intravenous ; Injections, Subcutaneous ; Intubation, Intratracheal ; Male ; Medical sciences ; Peptide ; Peptides - administration & dosage ; Peptides - blood ; Peptides - pharmacokinetics ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Powder inhalation ; Radioimmunoassay</subject><ispartof>International journal of pharmaceutics, 2004-05, Vol.276 (1), p.75-81</ispartof><rights>2004</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23</citedby><cites>FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15724476$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15113616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jansen, Mendel</creatorcontrib><creatorcontrib>Darby, Ian</creatorcontrib><creatorcontrib>Abribat, Thierry</creatorcontrib><creatorcontrib>Dubreuil, Pascal</creatorcontrib><creatorcontrib>Ferdinandi, Eckhardt S</creatorcontrib><creatorcontrib>Hardy, John G</creatorcontrib><title>Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administration is being considered as an alternative to subcutaneous injection. A study was undertaken in dogs to investigate the absorption of TH9507 following pulmonary delivery. Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38
μg/kg, respectively. In a separate study, male and female dogs received 100
μg/kg intravenously. Blood samples were collected at selected sampling times after dosing and plasma levels of TH9507 were measured by radioimmunoassay. The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%. No significant difference was observed for the terminal half-life of TH9507 after intratracheal (39
min) and subcutaneous (26
min) administrations. The mean residence time (MRT) was greater following intratracheal administration (74
min versus 52
min;
P<0.01). These data indicate that the delivery of the TH9507 by the inhalation route may provide a suitable alternative to subcutaneous injection.</description><subject>Absorption</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>Bioavailability</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Dogs</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Growth Hormone-Releasing Hormone - analogs & derivatives</subject><subject>Half-Life</subject><subject>hGRF</subject><subject>Injections, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Intubation, Intratracheal</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Peptide</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - blood</subject><subject>Peptides - pharmacokinetics</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Powder inhalation</subject><subject>Radioimmunoassay</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1DAQgC0EotvCT6DyBU6b4EdsZ08IVbRFqgSH5Ww59njXqyRe7KQV_x6vNlJ762nm8M3rG4Q-UVJTQuXXQx0Ox71JQ80IaWrCakLZG7SireIVb5R8i1aEq7YSVPELdJnzgRAiGeXv0QUVlHJJ5Qptf8_9EEeT_mEHfXiEkkSPt_cbQdQaG7xL8Wna431MBQOcoAeTw7jD3tgpJmxG08fdDGscRjztAbu4-4DeedNn-LjEK_Tn9sf25r56-HX38-b7Q2X5hk5V13UgjGKyZZJyJRqniFRCGOcdpw110jMjRNOA6KyjUgjnfLmPbWTLvWf8Cn059z2m-HeGPOkhZAt9b0aIc9bqBPP2BIozaFPMOYHXxxSGcrSmRJ906oNedOqTTk2YLjpL3fUyYO4GcM9Vi78CfF4Ak63pfTKjDfkFp1hTflG4b2cOio7HAElnG2C04EICO2kXwyur_AeNYJRs</recordid><startdate>20040519</startdate><enddate>20040519</enddate><creator>Jansen, Mendel</creator><creator>Darby, Ian</creator><creator>Abribat, Thierry</creator><creator>Dubreuil, Pascal</creator><creator>Ferdinandi, Eckhardt S</creator><creator>Hardy, John G</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040519</creationdate><title>Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog</title><author>Jansen, Mendel ; Darby, Ian ; Abribat, Thierry ; Dubreuil, Pascal ; Ferdinandi, Eckhardt S ; Hardy, John G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Absorption</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>Bioavailability</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Dogs</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Growth Hormone-Releasing Hormone - analogs & derivatives</topic><topic>Half-Life</topic><topic>hGRF</topic><topic>Injections, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Intubation, Intratracheal</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Peptide</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - blood</topic><topic>Peptides - pharmacokinetics</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Powder inhalation</topic><topic>Radioimmunoassay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jansen, Mendel</creatorcontrib><creatorcontrib>Darby, Ian</creatorcontrib><creatorcontrib>Abribat, Thierry</creatorcontrib><creatorcontrib>Dubreuil, Pascal</creatorcontrib><creatorcontrib>Ferdinandi, Eckhardt S</creatorcontrib><creatorcontrib>Hardy, John G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jansen, Mendel</au><au>Darby, Ian</au><au>Abribat, Thierry</au><au>Dubreuil, Pascal</au><au>Ferdinandi, Eckhardt S</au><au>Hardy, John G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2004-05-19</date><risdate>2004</risdate><volume>276</volume><issue>1</issue><spage>75</spage><epage>81</epage><pages>75-81</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administration is being considered as an alternative to subcutaneous injection. A study was undertaken in dogs to investigate the absorption of TH9507 following pulmonary delivery. Male beagle dogs were administered TH9507 by intratracheal dry powder insufflation and subcutaneous injection at doses of approximately 375 and 38
μg/kg, respectively. In a separate study, male and female dogs received 100
μg/kg intravenously. Blood samples were collected at selected sampling times after dosing and plasma levels of TH9507 were measured by radioimmunoassay. The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%. No significant difference was observed for the terminal half-life of TH9507 after intratracheal (39
min) and subcutaneous (26
min) administrations. The mean residence time (MRT) was greater following intratracheal administration (74
min versus 52
min;
P<0.01). These data indicate that the delivery of the TH9507 by the inhalation route may provide a suitable alternative to subcutaneous injection.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15113616</pmid><doi>10.1016/j.ijpharm.2004.02.012</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2004-05, Vol.276 (1), p.75-81 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71872382 |
| source | Elsevier |
| subjects | Absorption Animals Area Under Curve Bioavailability Biological and medical sciences Biological Availability Dogs Female General pharmacology Growth Hormone-Releasing Hormone - analogs & derivatives Half-Life hGRF Injections, Intravenous Injections, Subcutaneous Intubation, Intratracheal Male Medical sciences Peptide Peptides - administration & dosage Peptides - blood Peptides - pharmacokinetics Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Powder inhalation Radioimmunoassay |
| title | Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T00%3A09%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulmonary%20delivery%20of%20TH9507,%20a%20growth%20hormone%20releasing%20factor%20analogue,%20in%20the%20dog&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Jansen,%20Mendel&rft.date=2004-05-19&rft.volume=276&rft.issue=1&rft.spage=75&rft.epage=81&rft.pages=75-81&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2004.02.012&rft_dat=%3Cproquest_cross%3E71872382%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-bbbe5a72682613754d706755adfd3141d6f2a5544e5bcd1655ddf18729683ff23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71872382&rft_id=info:pmid/15113616&rfr_iscdi=true |